Skip to content

Post-lobectomy Use of Glucose for Pleurodesis and Air-leak Cessation. A Feasibility Trial.

Post-lobectomy Use of Glucose for Pleurodesis and Air-leak Cessation. A Feasibility Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02376218
Acronym
PLUG
Enrollment
10
Registered
2015-03-03
Start date
2015-04-30
Completion date
2016-02-29
Last updated
2016-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Surgical Procedures

Brief summary

It is common practice to leave a chest drainage catheter after lung surgical resections to manage air leaks. The air leakage will usually stop in the initial postoperative days, but in a few patients, it will last for a longer period of time, preventing the removal of the chest tube that can lead to patient discomfort, increased likelihood to develop postoperative complications and longer length of hospital stay. Pleurodesis is an effective method to address postoperative air leak which consists in injecting an irritating solution into the chest cavity. This is not performed regularly after lung resections for different reasons including associated pain, costs, and fear of infections. Pleurodesis with hyperosmolar glucose solution have been used for years with good results in some Asian countries because of its simplicity and low cost. Its effectiveness for pleurodesis has been reported in cases of spontaneous pneumothorax and chylothorax, but its efficiency to stop air leaks in the postoperative period remains to be defined.

Interventions

DRUGHypertonic 50% dextrose pleurodesis

Intrapleural administration of 180ml of hypertonic dextrose solution.

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years or older at the time of surgery * Having undergone a simple lung lobectomy for malignancy, primary or metastatic * Procedure performed through thoracotomy, sternotomy or video-assisted thoracic surgery (VATS), and associated or not to mediastinoscopy, staging thoracoscopy, mediastinal lymph nodes sampling or mediastinal lymph nodes dissection * Normally recovery after a surgery performed between 12 and 24 hours earlier

Exclusion criteria

* High amount of liquid drainage from chest tube (\>500 cc in the last 8 hours) * Minimal air leak (\<20 cc/min in one of the last 4 hours) * Large air leak (\>500 cc/min in one of the last 4 hours) * History of previous ipsilateral thoracotomy, lung resection, rib fracture, chest trauma, or lung/thoracic infection * Diabetes or hyperglycemia * Immunity disorders * Allergy to local anaesthetics * Hemodynamic instability * Need for respiratory support * Inability to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Air leak cessation48 hours after time of initial injection of 50% glucose solutionair leak \<20 cc/min for 4 hours or more

Secondary

MeasureTime frameDescription
Time to air leak cessation30-day post-operative period
Time to chest tube removal30-day post-operative period
Length of hospitalization30-day post-operative period
Postoperative complications30-day post-operative periodnumber of participants with one of the following: o Hyperglycemia o De novo atrial fibrillation o Pneumonia o Empyema o Thromboembolic disorders o Confusion o Need for discharge with chest tube o Recurrent pneumothorax o Need for chest tube reinsertion o Death

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026